The December 4, 2026 offer expiry is the key catalyst. Watch for Aurora shareholder response, potential competing bids from parties that have signed confidentiality agreements, and the Alberta Securities Commission decision on Curaleaf's application to halt Aurora's ATM program. A successful acquisition would create the largest global cannabis company by revenue.
Price Chart
Executive Summary
Curaleaf publicly challenges Aurora Cannabis's board for rejecting its enhanced US$5.00/share hostile bid, arguing the rejection is not in shareholders' best interests. The press release rebuts Aurora's stated reasons point-by-point, highlighting that Curaleaf is the only binding bidder yet is denied diligence access while other parties are granted it. The filing escalates the public-relations battle in the ongoing hostile takeover attempt, with the offer expiring December 4, 2026.
Key Facts
- Curaleaf's enhanced offer is US$5.00 per Aurora share (US$1.00 cash + 0.4013 Curaleaf shares), representing an 86% premium to Aurora's unaffected 30-day VWAP and a 217% premium on an ex-cash basis.
- Aurora's board again recommended rejection on October 14, 2026; Curaleaf responded on October 19, 2026.
- Curaleaf claims it is the only bidder with a binding offer and real money on the table, yet is denied due diligence access while other parties have signed confidentiality and standstill agreements.
- The enhanced offer expiry is December 4, 2026.
- Curaleaf has filed an application with the Alberta Securities Commission to halt Aurora's ATM share issuances.
- Pro forma financials show a combined entity with >US$1.5B LTM revenue and ~US$350M LTM Adjusted EBITDA.
Financial Impact
Enhanced offer values Aurora at US$5.00/share, an 86% premium to unaffected 30-day VWAP. Combined entity would have >US$1.5B LTM revenue and ~US$350M LTM Adjusted EBITDA.
Risk Factors
- Aurora's board continues to recommend rejection and has granted diligence access to other potential bidders, increasing risk of a competing offer or no deal.
- Regulatory hurdles in Canada and the U.S. could delay or block the transaction.
- Curaleaf's stock price volatility could affect the exchange ratio and total consideration.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (CURLF) — Batch item 1 | 0001756770-26-000131 |
| Document: curaleafchallengesaurora.htm | 0001756770-26-000130 |
| Document: 0001756770-26-000131-index-headers.html | 0001756770-26-000131 |
| Document: 0001756770-26-000131-index.html | 0001756770-26-000131 |
| Document: 0001756770-26-000131.txt | 0001756770-26-000131 |
| 8-K Filing (CURLF) — Batch item 6 | 0001756770-26-000130 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | 425 / 8-K | $7.86 $8.29 | ▲ +5.47% | ▲ +5.44% | $8.52 (+8.40%) |
Oct 6, 2026 21d ago | 425 | $9.99 $8.82 | ▼ −11.71% | ▼ −11.57% | $8.52 (−14.71%) |
Oct 6, 2026 21d ago | 8-K | $9.99 $8.82 | ▼ −11.71% | ▼ −11.57% | $8.52 (−14.71%) |
Oct 6, 2026 21d ago | 425 | $9.99 $8.82 | ▼ −11.71% | ▼ −11.57% | $8.52 (−14.71%) |
Oct 6, 2026 21d ago | 8-K | $9.99 $8.82 | ▼ −11.71% | ▼ −11.57% | $8.52 (−14.71%) |
Oct 1, 2026 25d ago | 8-K | $9.95 $9.39 | ▼ −5.63% | ▼ −6.79% | $8.52 (−14.37%) |
Oct 1, 2026 25d ago | 8-K | $9.95 $9.39 | ▼ −5.63% | ▼ −6.79% | $8.52 (−14.37%) |
Sep 16, 2026 5w ago | 8-K | $9.98 $11.62 | ▲ +16.43% | ▲ +13.60% | $8.52 (−14.63%) |
Sep 16, 2026 5w ago | 425 | $9.98 $11.90 | ▲ +19.24% | ▲ +17.16% | $8.52 (−14.63%) |
Sep 15, 2026 6w ago | 425 / 8-K | $10.12 $10.45 | ▲ +3.26% | ▲ +2.44% | $8.52 (−15.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers